• AIM ImmunoTech Inc. is seeking stockholder approval for highly dilutive financings and a potential reverse stock split due to disclosed liquidity strain.
  • The company explicitly warned that failure to raise additional capital in the very near term could force substantial cutbacks or even a voluntary bankruptcy filing.
  • This overshadows recent positive clinical trial updates for its DURIPANC study evaluating Ampligen in pancreatic cancer.